120 West 45th Street
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services to accelerate and increase the efficiency of drug discovery for its clients, which include all major pharmaceutical and biotechnology companies worldwide, as well as leading materials science researchers. Schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and was a co-founder of leading biotech companies including Nimbus Therapeutics, Morphic Therapeutic, and others. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science.
A great company is made up of great people, and Schrödinger is no exception. Whether you’re in Administration, Sales, Finance, Law, Engineering, IT, or Science, we are always on the lookout for exceptional candidates who can join us and make our team stronger. You will find Schrödinger to be a dynamic, energetic, and fast-paced place to work, where you get to interact with some of the smartest and hardest working people you’ll ever meet. If you’ve ever had a curiosity about science, and how science can improve people’s lives, then there’s no
better place to be than Schrödinger.
Stock Exchange: NASDAQ
Stock Symbol: SDGR
72 articles with Schrödinger
Schrödinger and WuXi AppTec Announce the Launch of Faxian Therapeutics to Enable Accelerated Drug Discovery
The new venture will leverage the precision molecular design platforms developed by Schrödinger and accelerate them through partnership with the world-class lead optimization services provided by WuXi AppTec.
Schrödinger, Inc. announced today that the Company will participate in a panel discussion entitled "Emerging Innovators - An Introduction to Biotech Privates" at the Citi 13th Annual Biotech Conference
Schrödinger Announces Oncology Collaboration with Canada’s National Centre for Drug Research and Development to Develop Novel Biologics
Collaboration to utilize Schrödinger’s advanced computation platform technology to accelerate discovery of immuno-oncology and other cancer biologics
Schrödinger and Tri-Institutional Therapeutics Discovery Institute Renew Agreement to Provide Drug Discovery Software to Tri-Institutional Researchers
Schrödinger, Inc. and the Tri-Institutional Therapeutics Discovery Institute, Inc.have renewed and extended, for an additional five years, an agreement reached in 2014 to provide access to Schrödinger's Materials Science, Biologics, and Small?Molecule Drug Discovery Suites to researchers within TRI-I TDI's member institutions.
SCI utilizes a network of Cryo-EM centers including the New York Structural Biology Center, Stanford University, and China's Tsinghua University, with anticipated expansion to include additional institutions.
Schrodinger and ShanghaiTech University to Establish Center of Excellence (COE) and Form Strategic Partnership
Schrodinger and ShanghaiTech University will embark on joint research projects to solve challenging scientific problems in molecular recognition of the human body that can lead to co-discoveries.
Dr. Goldstein brings to Schrödinger over 20 years of strategic financial experience in the healthcare sector.
$4,829-Per-Hour Supercomputer Built on Amazon Cloud to Fuel Cancer Research, Schrodinger, Inc. Reveals